In a recent study of pancreatic cancer, IL-33 has been reported to activate ILC2s that further induce tertiary lymphoid structures (lymphoid aggregates that in chronically inflamed tissues, including cancer, infection and inflammation) (Amisaki et al., 2025). Here, IL33 is linked to familial pancreatic carcinoma.